{
    "clinical_study": {
        "@rank": "40382", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment."
            }, 
            {
                "arm_group_label": "Treatment Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This single center, open-label, randomized study will investigate the drug-drug interaction\n      potential between multiple doses of RO7033877 and multiple doses of colistin\n      methanesulfonate sodium (CMS)."
        }, 
        "brief_title": "A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female (of non childbearing potential) healthy volunteers between 18 to\n             55 years\n\n          -  Body mass index (BMI) between 18 and 30 kg/m2\n\n          -  Non smokers\n\n          -  Use adequate contraception methods\n\n        Exclusion Criteria:\n\n          -  Evidence of active of chronic disease\n\n          -  Regular consumption of drugs of abuse\n\n          -  Infection with human immunodeficiency virus (HIV), hepatits B (HBV) or hepatitis C\n             (HCV)\n\n          -  History of significant allergic reactions\n\n          -  Abnormal blood pressure\n\n          -  Clinically significant abnormalities (e.g. cadiovascular, laboratory values)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156323", 
            "org_study_id": "NP29333", 
            "secondary_id": "2014-000108-86"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Sequence 1", 
                    "Treatment Sequence 2"
                ], 
                "description": "Multiple doses of RO7033877 over 2.5 days", 
                "intervention_name": "RO7033877", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Sequence 1", 
                    "Treatment Sequence 2"
                ], 
                "description": "Multiple doses of CMS over 2.5 days", 
                "intervention_name": "CMS", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Sequence 1", 
                    "Treatment Sequence 2"
                ], 
                "description": "Multiple doses of RO7033877 and CMS over 2.5 days", 
                "intervention_name": "RO7033877 + CMS", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Colistin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, TWO SEQUENCE, 3-WAY CROSSOVER STUDY TO INVESTIGATE THE INTERACTION BETWEEN MULTIPLE DOSES OF COLISTIN METHANESULFONATE SODIUM (CMS) AND MULTIPLE DOSES OF RO7033877 IN HEALTHY SUBJECTS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: NP29333 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Multiple dose pharmacokinetics of RO7033877 and colistin/CMS (as appropriate): Cmax and area under the concentration-time curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "up to 4 days (for each period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156323"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "Up to 9 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}